Trump to visit Fed on Thursday amid Powell feud, renovation probe
Investing.com - Argenx SE (NASDAQ:ARGX) stock received a vote of confidence as H.C. Wainwright reiterated its Buy rating and $720.00 price target on the biopharmaceutical company. According to InvestingPro data, analysts maintain a strong bullish consensus on ARGX, with price targets ranging from $586 to $1,113. The stock, currently trading at $551, appears undervalued based on InvestingPro’s Fair Value analysis.
The reaffirmation follows argenx’s announcement that ARGX-119, a muscle-specific kinase (MuSK) agonist antibody, has advanced to late-stage clinical development, becoming the company’s third molecule to reach this milestone after efgartigimod and empasiprubart. The company, which boasts a market capitalization of $33.7 billion and maintains a "GREAT" financial health score on InvestingPro, has demonstrated impressive revenue growth of 82% over the last twelve months.
The decision to move ARGX-119 forward was based on positive topline data from a proof-of-concept Phase 1b study in DOK7-CMS patients, with detailed results scheduled for presentation at an upcoming medical meeting.
The Phase 1b study enrolled 16 DOK7-CMS patients randomized in a 4:1 ratio to receive either ARGX-119 or placebo through IV infusions during a 12-week treatment period, followed by a nearly seven-month follow-up period.
According to H.C. Wainwright, the study met its primary endpoint by demonstrating favorable safety and tolerability among patients, while also measuring pharmacokinetics, immunogenicity, and efficacy metrics including the six-minute walk test, quantitative myasthenia gravis score, and myasthenia gravis activities of daily living score.
In other recent news, argenx SE has been the focus of multiple developments. The U.S. Food and Drug Administration (FDA) is evaluating a potential safety signal related to argenx’s Vyvgart Hytrulo, specifically concerning a severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Despite this, Citi has maintained its Buy rating with a price target of $803, emphasizing that the FAERS data lacks important details. In contrast, JMP Securities slightly lowered its price target for argenx to $699 but kept an Outperform rating, noting the company’s strong first-quarter financial performance in 2025 and ongoing success of the VYVGART franchise.
Meanwhile, TD Cowen reiterated its Buy rating and a $761 price target following promising trial results for VYVGART in myositis and Sjogren’s disease, highlighting the therapy’s potential for significant upside. Additionally, H.C. Wainwright reaffirmed its Buy rating with a $720 price target, emphasizing Vyvgart’s unique position in treating myasthenia gravis and the potential benefits of personalized treatment approaches. These analyst perspectives reflect a generally positive outlook on argenx’s strategic initiatives and its ongoing research and development efforts. The company’s endeavors in advancing its pipeline and exploring new delivery methods for its products are seen as significant growth drivers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.